News | March 10, 2026
Hopewell Therapeutics sublicenses breakthrough LNP technology to Foxcroft for cancer vaccine development
The two companies will collaborate to evaluate Hopewell’s ttLNPs for clinical applications
The two companies will collaborate to evaluate Hopewell’s ttLNPs for clinical applications
Subscribe To Our Newsletter & Stay Updated